Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Strategic Pivot | Arbutus Biopharma refocuses on lead siRNA candidate imdusiran for chronic hepatitis B treatment, extending cash runway to Q4 2026 through restructuring |
Promising Trial Results | Explore imdusiran's efficacy in combination with interferon, showcasing potential as a cornerstone therapy for chronic hepatitis B |
Legal Victories | Delve into Arbutus' favorable rulings against Moderna in lipid nanoparticle technology patent disputes, potentially unlocking significant financial benefits |
Analyst Outlook | JMP Securities maintains Market Outperform rating with price targets ranging from $4.00 to $5.00, reflecting confidence in Arbutus' strategic direction |
Metrics to compare | ABUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.4x | −9.2x | −0.7x | |
PEG Ratio | −1.04 | −0.17 | 0.00 | |
Price/Book | 6.0x | 2.0x | 2.6x | |
Price / LTM Sales | 95.8x | 19.7x | 3.2x | |
Upside (Analyst Target) | 46.5% | 38.8% | 46.4% | |
Fair Value Upside | Unlock | 3.6% | 6.9% | Unlock |